Teva Pharmaceutical (TEVA) officer settles 15,723 RSUs into ordinary shares

Rhea-AI Filing Summary

Teva Pharmaceutical Industries officer Mark Sabag reported the vesting and settlement of 15,723 restricted share units on March 5, 2026. These units were converted at $0.00 per share into 15,723 ordinary shares, increasing his direct holdings to 287,042 ordinary shares.

Following the transaction, he also held 47,170 restricted share units. The RSUs were originally granted on March 5, 2025, with additional tranches of 15,723 vesting on March 5, 2027 and March 5, 2028, and 15,724 vesting on March 5, 2029. Each RSU represents a right to one ordinary share or its cash value.

Insider Trade Summary

15,723 shares exercised/converted

Mixed 2 txns

Insider Sabag Mark

Role See "Remarks"

Type	Security	Shares	Price	Value
Exercise	Restricted Share Units	15,723	$0.00	--
Exercise	Ordinary Shares	15,723	$0.00	--

Holdings After Transaction: Restricted Share Units — 47,170 shares (Direct); Ordinary Shares — 287,042 shares (Direct)

Footnotes (1)

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Restricted share units were granted on March 5, 2025, with 15,723 vested on March 5, 2026, 15,723 vesting on each of March 5, 2027 and March 5, 2028, and 15,724 vesting on March 5, 2029.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sabag Mark

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV L3 6944020

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See "Remarks"

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	03/05/2026		M		15,723	A	(2)	287,042	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(2)	03/05/2026		M			15,723	(3)	(3)	Ordinary Shares(1)	15,723	$0	47,170	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

3. Restricted share units were granted on March 5, 2025, with 15,723 vested on March 5, 2026, 15,723 vesting on each of March 5, 2027 and March 5, 2028, and 15,724 vesting on March 5, 2029.

Remarks:

Executive Vice President, International Markets Commercial

	/s/ Dov Bergwerk as attorney-in-fact for Mark Sabag	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did TEVA officer Mark Sabag report?

Mark Sabag reported the vesting and conversion of 15,723 restricted share units into 15,723 ordinary shares at $0.00 per share. This derivative exercise increased his directly held ordinary shares and reflects scheduled equity compensation vesting.

How many TEVA ordinary shares does Mark Sabag hold after this Form 4?

After the March 5, 2026 transaction, Mark Sabag directly holds 287,042 ordinary shares of Teva Pharmaceutical Industries. This figure reflects the addition of 15,723 newly issued shares from vested restricted share units settled at no exercise price.

What restricted share unit balance does Mark Sabag retain in TEVA?

Following the vesting of 15,723 units, Mark Sabag continues to hold 47,170 restricted share units. These RSUs represent contingent rights to receive either ordinary shares or, at the committee’s option, the cash value of one ordinary share at future settlement dates.

What is the vesting schedule for Mark Sabag’s TEVA restricted share units?

Restricted share units were granted on March 5, 2025, with 15,723 vesting on March 5, 2026, 15,723 vesting on March 5, 2027 and March 5, 2028, and 15,724 vesting on March 5, 2029. Each vesting date unlocks additional equity-based compensation.

How are TEVA restricted share units settled for Mark Sabag?

Each restricted share unit represents a contingent right to receive one ordinary share or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share. Settlement occurs at vesting, as shown by the March 5, 2026 conversion.

Can TEVA ordinary shares be held as American Depositary Shares?

Yes. Teva’s ordinary shares may be represented by American Depositary Shares, with each ADS currently representing one ordinary share. This structure allows trading through depositary receipts while maintaining an underlying one-to-one relationship with ordinary shares.